These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32320737)

  • 21. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.
    Northcott PA; Shih DJ; Remke M; Cho YJ; Kool M; Hawkins C; Eberhart CG; Dubuc A; Guettouche T; Cardentey Y; Bouffet E; Pomeroy SL; Marra M; Malkin D; Rutka JT; Korshunov A; Pfister S; Taylor MD
    Acta Neuropathol; 2012 Apr; 123(4):615-26. PubMed ID: 22057785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.
    Genovesi LA; Millar A; Tolson E; Singleton M; Hassall E; Kojic M; Brighi C; Girard E; Andradas C; Kuchibhotla M; Bhuva DD; Endersby R; Gottardo NG; Bernard A; Adolphe C; Olson JM; Taylor MD; Davis MJ; Wainwright BJ
    Genome Med; 2021 Jun; 13(1):103. PubMed ID: 34154646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M; Ramaswamy V; Taylor MD
    Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
    Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
    Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic transcriptomic analysis of childhood medulloblastoma identifies N6- methyladenosine-dependent lncRNA signatures associated with molecular subtype, immune cell in
    Joshi K; Yuan M; Katsushima K; Saulnier O; Ray A; Amankwah E; Stapleton S; Jallo G; Taylor MD; Eberhart CG; Perera RJ
    Res Sq; 2024 Sep; ():. PubMed ID: 39281885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas.
    Bharambe HS; Paul R; Panwalkar P; Jalali R; Sridhar E; Gupta T; Moiyadi A; Shetty P; Kazi S; Deogharkar A; Masurkar S; Yogi K; Kunder R; Gadewal N; Goel A; Goel N; Chinnaswamy G; Ramaswamy V; Shirsat NV
    Acta Neuropathol Commun; 2019 Apr; 7(1):52. PubMed ID: 30944042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
    Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
    Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort.
    Wang Y; Huang J; Yin X; Xu Q; Sun Y; Yao Y; Xiong J
    Acta Neurochir (Wien); 2024 Feb; 166(1):72. PubMed ID: 38329556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
    Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
    J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Prognostic Implications of Wnt Hub Genes Expression in Medulloblastoma.
    Martins-da-Silva A; Baroni M; Salomão KB; das Chagas PF; Bonfim-Silva R; Geron L; Cruzeiro GAV; da Silva WA; Corrêa CAP; Carlotti CG; de Paula Queiroz RG; Marie SKN; Brandalise SR; Yunes JA; Scrideli CA; Valera ET; Tone LG
    Cell Mol Neurobiol; 2023 Mar; 43(2):813-826. PubMed ID: 35366170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.
    Zhou M; Zhao H; Wang Z; Cheng L; Yang L; Shi H; Yang H; Sun J
    J Exp Clin Cancer Res; 2015 Sep; 34(1):102. PubMed ID: 26362431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Texture Analysis of T1-Weighted Contrast-Enhanced Magnetic Resonance Imaging Potentially Predicts Outcomes of Patients with Non-Wingless-Type/Non-Sonic Hedgehog Medulloblastoma.
    Li J; Chen C; Fu R; Zhang Y; Fan Y; Xu J; Cen Y
    World Neurosurg; 2020 May; 137():e27-e33. PubMed ID: 31589984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma.
    Vaillant C; Valdivieso P; Nuciforo S; Kool M; Schwarzentruber-Schauerte A; Méreau H; Cabuy E; Lobrinus JA; Pfister S; Zuniga A; Frank S; Zeller R
    PLoS One; 2015; 10(4):e0124870. PubMed ID: 25901736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
    Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
    J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. G-protein coupled receptor expression patterns delineate medulloblastoma subgroups.
    Whittier KL; Boese EA; Gibson-Corley KN; Kirby PA; Darbro BW; Qian Q; Ingram WJ; Robertson T; Remke M; Taylor MD; O'Dorisio MS
    Acta Neuropathol Commun; 2013 Oct; 1():66. PubMed ID: 24252460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells.
    Panwalkar P; Moiyadi A; Goel A; Shetty P; Goel N; Sridhar E; Shirsat N
    J Mol Neurosci; 2015 Jul; 56(3):673-80. PubMed ID: 25859932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are molecular subgroups of medulloblastomas really prognostic?
    Frappaz D; Faure-Conter C; Meyronet D; Levard-Bonneville A; Beuriat PA; Sunyach MP; Barritault M
    Curr Opin Neurol; 2018 Dec; 31(6):747-751. PubMed ID: 30300240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.
    Ma B; Li Y; Ren Y
    Cancer Med; 2020 Jan; 9(1):335-349. PubMed ID: 31743579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.